Baseline SDI Domains and LLDAS Outcomes in SLE Patients Receiving Belimumab

№ files_lp_4_process_2_71169

File format: docx Character count: 10300 File size: 27 KB

Year: 2026

Study Type: Clinical research supplementary material

Patient Population: Systemic Lupus Erythematosus (SLE) patients

Treatment: Belimumab

Outcome Measures: Lupus Low Disease Activity State (LLDAS), cSLEDAI-2K = 0

Data Type: Statistical tables, logistic regression results

SDI: Systemic Lupus International Collaborating Clinics / American College of Rheumatology Damage Index

Significant Findings: Highlighted P values for cognitive impairment and musculoskeletal outcomes

Time Frame: Week 52 after treatment initiation

Variables Assessed: Ocular, neuropsychiatric, renal, pulmonary, cardiovascular, peripheral vascular, gastrointestinal, musculoskeletal, skin, endocrine, malignancy

Analysis Method: Simple logistic regression, odds ratios with 95% confidence intervals

By placing an order, you agree to the Terms of Use and acknowledge that access to digital materials is provided after payment and is non-refundable, except in cases where the material is not actually accessible.

Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:

Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
In the app, tap Send.
Select network, paste our wallet address.
Send the exact amount shown above.

After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.

Supplementary Figures and Tables on the Metabolite Analysis of SLE Patients

Year: 2026

Region / City: Global

Topic: Metabolomics, Systemic Lupus Erythematosus (SLE), Machine Learning

Document Type: Research Supplementary Data

Organization / Institution: Various Research Institutes

Author: Multiple Authors

Target Audience: Researchers, Medical Scientists, Healthcare Professionals

Period of Validity: N/A

Approval Date: N/A

Date of Changes: N/A

Topics: LLDAS Belimumab SLE

The project is focused on storing and searching highly specialized data that is rarely indexed by major search engines.

The content of this website is protected under applicable copyright laws, including but not limited to the Copyright Act and relevant legislation of the European Union. Any use of the content, including reproduction, distribution, public communication, modification, or other processing, is prohibited without the prior written consent of the rights holder, unless expressly permitted by law. Users are permitted to use the content solely for personal purposes within the scope defined by copyright legislation. Any other use, including commercial use, requires the prior written authorization of the rights holder. Trademarks, trade names, logos, and other identifiers displayed on this website may be registered trademarks of their respective owners. Any use without the authorization of the relevant rights holder is prohibited. The website operator does not guarantee the accuracy, completeness, or timeliness of the information provided and shall not be liable for any damage or loss resulting from its use, except where required by mandatory legal provisions.

Reproduction of materials is permitted only if a link to speakdot.com is included.